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Abstract
Background: Genetic variation in NOD2 and cigarette smoking are well-established risk factors for the
development of Crohn’s disease (CD). However, little is known about a potential interaction between these risk
factors. We investigated gene-environment interactions between CD-associated NOD2 alleles and cigarette smoking
in a large sample of patients with CD.
Methods: Three previously reported CD-associated variants in NOD2 (R702W, G908R, 1007fs) were genotyped in
1636 patients with CD continuously recruited between 1995 and 2010 based on physician referral. Data on history
of smoking behaviour was obtained for all participants through a written questionnaire. Using a case-only design,
we performed logistic regression analyses to investigate statistical interactions between NOD2 risk alleles and
smoking status.
Results: We detected a significant negative interaction between carriership of at least one of the NOD2 risk alleles
and history of ever having smoked (OR = 0.71; p = 0.005) as well as smoking at the time of CD diagnosis (OR =
0.68; p = 0.005). Subsequent separate analyses of the three variants revealed a significant negative interaction
between the 1007fs variant and history of ever having smoked (OR = 0.64; p =9×1 0
-4) and smoking at the time
of CD diagnosis (OR = 0.53; p =7×1 0
-5).
Conclusions: The observed significant negative gene-environment interaction suggests that the risk increase for
CD conferred simultaneously by cigarette smoking and the 1007fs NOD2 polymorphism is smaller than expected
and may point to a biological interaction. Our findings warrant further investigation in epidemiological and
functional studies to elucidate pathophysiology as well as to aid in the development of recommendations for
disease prevention.
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Background
Crohn’s disease (CD) is a common form of inflamma-
tory bowel disease (IBD) characterised by chronic relap-
sing and remitting episodes of transmural inflammation
of the gastrointestinal tract. High rates of CD are found
in North America (including Canada), northern Europe,
and the United Kingdom, with an estimated 47,000 new
cases diagnosed each year in North America and 41,000
new cases diagnosed each year in Europe [1]. The dis-
ease burden of CD is high, often associated with compli-
cations such as intestinal strictures, fistulas, and
granulomas, the need for surgical intervention, and
extraintestinal manifestations [2]. It is believed that
immune tolerance to normal intestinal bacteria is
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any medium, provided the original work is properly cited.disturbed in genetically susceptible individuals, leading
to a pathogenic inflammatory response [3].
Evidence from twin and familial aggregation studies
[4], as well as more recent evidence from genome-wide
association studies [5] suggests that genetic factors play
an important role in CD aetiology. Among the first and
most consistently replicated genetic associations discov-
ered in CD were three variants in NOD2 (nucleotide-
binding oligomerisation domain containing 2; previously
known as CARD15) [6,7], which represent the strongest
genetic risk factors for CD identified to date [8]. NOD2,
an intracellular sensor of bacteria-derived muramyl
dipeptide, plays an essential role in regulating host
response to intestinal bacteria [9,10]. The three main
reported disease-associated polymorphisms (R702W,
G908R, and 1007fs) all lie within or near a leucine rich
repeat domain, and it is thought that these three CD-
associated variants contribute to disease pathogenesis
through interference with bacterial recognition [11,12].
Associations between CD and the three main suscept-
ibility variants are well-established [11,13,14] with a
recent meta-analysis revealing disease odds ratios (OR)
under a dominant genetic model of 2.2 (95% CI 2.0-2.5)
for the R702W polymorphism, 2.6 (95% CI 2.2-2.9) for
G908R, and 3.8 (95% CI 3.4-4.3) for 1007fs [15]. When
data for all three variants are combined, the disease OR
associated with simple heterozygotes is 2.4 (95% CI 2.0-
2.8) and for compound heterozygotes is 9.0 (95% CI 6.0-
13.5) [15].
While the association of NOD2 variants with CD is
confirmed, the relatively small effect size of disease-asso-
ciated NOD2 alleles even among homozygotes [16] and
the observation that NOD2 knock-out mice do not
develop spontaneous intestinal inflammation [9] indicate
that additional factors are necessary for disease patho-
genesis. Several environmental factors such as appen-
dectomy, dietary factors, domestic hygiene, oral
contraceptive use, and childhood infections have been
implicated in CD [17], but the most consistent epide-
miological evidence points to a clear risk associated with
cigarette smoking [18,19], which is the strongest envir-
onmental risk factor identified for CD to date [20]. Two
meta-analyses reveal that current cigarette smokers are
up to twice as likely to develop CD as non-smokers (OR
= 1.8-2.0) [21,22]. Furthermore, cigarette smoking is
known to compromise innate and adaptive immune
responses, leading to increased susceptibility to micro-
bial infections [23], supporting its potential role in the
pathogenesis of CD.
It has been speculated that an interaction between
genetic and environmental factors is necessary for the
development of complex genetic disorders including CD
[24]. Although gene-environment interactions have
often been invoked in explaining the aetiology of CD
[25], studies of these interactions in CD have thus far
received little research attention. Given the established
role of NOD2 in regulating innate immune responses
and cigarette smoke’s impact on innate immunity, it is
plausible that cigarette smoking might modulate the
functional consequences of CD-associated polymorph-
isms in NOD2.
In this study, we used a case-only design to investigate
potential gene-environment interactions between cigar-
ette smoking and susceptibility variants in NOD2 among
patients with CD. The case-only study design quantifies
gene-environment interaction using the interaction odds
ratio. Using this measure, the observed effect of both
variables combined is compared to the hypothetical
effect size when the effect of both factors is multiplied.
Accordingly, an interaction odds ratio of 1.0 suggests
the absence of interaction, whereas an interaction OR
significantly greater than 1.0 suggests positive (synergis-
tic) interaction and an interaction OR significantly less
than 1.0 suggests negative (antagonistic) interaction. We
hypothesised that the interaction between disease-asso-
ciated NOD2 alleles and history of smoking would devi-
ate from multiplicativity with regard to risk increase for
CD (i.e. interaction OR significantly greater than or less
than 1.0), thus being potentially indicative of biological
interaction. We further hypothesised that this deviation
would be more pronounced among patients who were
active smokers at the time of CD diagnosis. The current
study represents the largest study to date to examine
statistical gene-environment interactions in patients with
CD and the first to employ a case-only design.
Results
Study sample characteristics
Table 1 provides demographic and risk factor character-
istics for the 1636 participants in the analytic sample
according to smoking status. Data regarding history of
ever having smoked was available for all 1636 partici-
pants. Smoking status at time of diagnosis was available
for 1283 (78%) participants. The study sample included
various subsamples recruited at different time points.
Information on smoking at diagnosis was missing for
the majority of patients in a single subsample with a
high frequency of family history (n = 450, recruited
from 2002 to 2004, 68.5% with missing data). However,
a sensitivity analysis excluding this subsample did not
significantly alter the results (Additional file 1: Table S1)
and therefore, this subsample was included in the final
analytic sample. Using a control population from the
popgen biobank as a comparison group, we confirmed
smoking as a risk factor for Crohn’s disease in our study
population (OR (95% CI) 1.24 (1.04-1.47), p = 0.016 for
ever having smoked). Genotype data is also summarised
in Table 1. Genotype status of all three polymorphisms
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ple was largely comprised of women (69%). Female
participants were slightly more likely than male parti-
cipants to have been smokers at the time of CD diag-
nosis (p = 0.02). Participants who had ever smoked
were on average older at diagnosis (mean age ever
smokers 27.4 years, never smokers 24.1 years; p <
0.001) and at study inclusion (mean age ever smokers
40.8 years, never smokers 36.3 years; p <0 . 0 0 1 )t h a n
those who had no history of smoking. Similarly, indivi-
duals who were smokers at the time of disease diagno-
sis were on average older at diagnosis (mean age
smokers 27.3 years, non-smokers 26.0 years; p = 0.03)
and study inclusion (mean age smokers 41.1 years,
non-smokers 38.8 years; p < 0.001) than non-smokers
at diagnosis. Carriers of at least one CD-associated
NOD2 allele were diagnosed at a younger age (mean
age at diagnosis 25.1 years) than participants who
were wild type at all three loci (mean age at diagnosis
26.8 years; p < = 0.001; Additional file 1: Table S2).
Analyses of each polymorphism separately indicated
that the 1007fs allele was the only polymorphism asso-
ciated with an earlier age at diagnosis (mean age at
diagnosis for carriers 24.6 years; mean age at diagnosis
for non-carriers 26.5 years; p = 0.001; Additional file
1: Table S2). Age at diagnosis was not associated with
the R702W and G908R polymorphisms. Sex, age at
study inclusion, and family history of IBD were not
associated with genotype for any of the three risk var-
iants (Additional file 1: Table S2). A positive family
history of IBD was not associated with smoking status
in probands (p = 0.08, Chi square analysis). Analyses
comparing the study participants included and
excluded from the final analyses revealed no signifi-
cant differences with regard to sex, smoking status,
age at study inclusion, or genotype at any of the three
loci (Additional file 1: Table S3). Excluded participants
were diagnosed at a slightly younger age than included
participants (24.8 years vs. 26.8 years; p <0 . 0 0 1 ;A d d i -
tional file 1: Table S3).
Table 1 Distribution of demographic and risk factor characteristics for all participants in analytic sample by smoking
status
Ever
Smokers
Never
Smokers
Smokers at
Diagnosis
Non-Smokers at
Diagnosis
Total
Sample
Characteristic n % n % p-value n % n % p-value n %
Total Participants n = 1636 945 57.8% 691 42.2% 522 40.7% 761 59.3% 1636 100.0%
Sex 0.09 0.02
Men 281 29.7% 233 33.7% 144 27.6% 258 33.9% 514 31.4%
Women 664 70.3% 458 66.3% 378 72.4% 503 66.1% 1122 68.6%
Age at Inclusion–Mean
(Standard Deviation)
40.8 ± 10.9 36.3 ± 12.9 2×1 0
-13 41.1 ± 10.6 38.8 ± 13.5 6×1 0
-4 38.9 ± 12.0
Age at Diagnosis–Mean
(Standard Deviation)
27.4 ± 10.1 24.1 ± 10.1 7×1 0
-11 27.3 ± 9.5 26.0 ± 11.4 0.03 26 ± 10.3
Family History 0.17 0.43
Yes 229 24.2% 196 28.4% 75 14.4% 128 16.8% 425 26.0%
No 463 49.0% 320 46.3% 295 56.5% 408 53.6% 783 47.9%
Unknown 253 26.8% 175 25.3% 152 29.1% 225 29.6% 428 26.2%
Combined Allele Analysis 1 × 10
-4 0.001
Wild Type 549 58.1% 336 48.6% 311 59.6% 384 50.5% 885 54.1%
Carrier of ≥ 1 risk allele 396 41.9% 355 51.4% 211 40.4% 377 49.5% 751 45.9%
R702W Polymorphism 0.12 0.34
Wild Type (C/C) 776 82.1% 540 78.1% 429 82.2% 608 79.9% 1316 80.4%
Heterozygote for risk allele (C/T) 153 16.2% 134 19.4% 85 16.3% 133 17.5% 287 17.5%
Homozygote for risk allele (T/T) 16 1.7% 17 2.5% 8 1.5% 20 2.6% 33 2.0%
G908R Polymorphism 0.93 0.12
Wild Type (G/G) 858 90.8% 626 90.6% 475 91.0% 689 90.5% 1484 90.7%
Heterozygote for risk allele (G/C) 84 8.9% 62 9.0% 47 9.0% 66 8.7% 146 8.9%
Homozygote for risk allele (C/C) 3 0.3% 3 0.4% 0 0.0% 6 0.8% 6 0.4%
1007fs Polymorphism 1 × 10
-4 7×1 0
-6
Wild Type (-/-) 735 77.8% 477 69.0% 420 80.5% 524 68.9% 1212 74.1%
Heterozygote for risk allele (-/C) 174 18.4% 166 24.0% 88 16.9% 187 24.6% 340 20.8%
Homozygote for risk allele (C/C) 36 3.8% 48 6.9% 14 2.7% 50 6.6% 84 5.1%
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We observed a significant departure from multiplicativ-
ity between carriership of at least one of the three risk
variants and history of ever having smoked (OR estimate
of departure from multiplicativity adjusted for age at
diagnosis, age at recruitment, sex, family history of IBD,
and year of recruitment (AOR) = 0.71, 95% CI 0.56-
0.90; Table 2) and history of smoking at the time of CD
diagnosis (AOR = 0.68, 95% CI 0.51-0.89; Table 3).
Upon analysis of individual polymorphisms, we observed
a significant departure from multiplicativity only
between the 1007fs risk allele and history of ever having
smoked (AOR = 0.64, 95% CI 0.49-0.83; Table 2) and
history of smoking at time of CD diagnosis (AOR =
0.53, 95% CI 0.39-0.73; Table 3). We found no evidence
for interaction between the R702W and G908R risk
alleles and history of ever smoking or smoking status at
the time of diagnosis.
Discussion
In an investigation of statistical interactions between
cigarette smoking and CD-associated NOD2 polymorph-
isms, we found a significant negative interaction
between the NOD2 1007fs polymorphism and cigarette
smoking. We did not observe this interaction for the
R702W or G908R polymorphisms. For both smoking
variables analysed, i.e. history of ever having smoked
and smoking status at the time of diagnosis, the
observed interaction OR between smoking and the
1007fs allele was lower than expected. These results
indicate that the increase in disease risk conferred by
both cigarette smoking and the 1007fs allele is signifi-
cantly lower than would be expected under a multiplica-
tive model. Accordingly, the lower than expected disease
risk in individuals who both carry the risk allele and
smoke suggests a negative interaction between both
factors.
It is possible that age of disease diagnosis and family
history of IBD might confound these results, especially
given the earlier age of disease diagnosis associated with
the 1007fs variant. However, our final model was
adjusted for age at diagnosis and family history, which
controls for potential confounding effects. Furthermore,
family history of IBD was not associated with smoking
status in our cohort. This indicates that age at diagnosis
and family history of IBD do not confound our results.
The strong negative interaction between cigarette
smoking and the 1007fs variant is intriguing given the
conflicting data from previous research. Statistical inter-
actions between CD-associated NOD2 variants and
smoking were previously investigated in two case-con-
trol studies, which failed to identify any statistical inter-
actions between smoking status and NOD2 genotypes
[13,26]. These studies, however, were limited by small
sample sizes and lacked the statistical power to detect
interactions of the size identified in our study. However,
two small studies have suggested that smokers and non-
smokers with CD have differences in their genetic back-
grounds, including variants in NOD2, with the 1007fs
variant found more commonly among non-smokers
[27,28]. These previous findings are consistent with our
results of a negative interaction between cigarette smok-
ing and the 1007fs allele. Taken together, these data are
suggestive that cigarette smoking modifies the disease
risk associated with the 1007fs variant, and the increase
in disease risk for smokers who carry this susceptibility
allele compared to non-smokers who carry this allele is
significantly less than expected.
To our knowledge the current study represents the
largest analysis to date of statistical gene-environment
Table 2 Departure from multiplicativity between CD-associated NOD2 alleles and ever smoking status among patients
with Crohn’s disease
Smoking status Unadjusted Adjusted*
Ever smoked Never smoked OR 95% CI p-value OR 95% CI p-value
Combined Allele Analysis
Wild type at all 3 loci 549 (58.1%) 336 (48.6%) 1.00 - - 1.00 - -
Carrier of ≥ 1 risk allele 396 (41.9%) 355 (51.4%) 0.68 0.56-0.83 1 × 10
-4 0.71 0.56-0.90 0.005
R702W Polymorphism
Wild type 776 (82.1%) 540 (78.1%) 1.00 - - 1.00 - -
Carrier of risk allele 169 (17.9%) 151 (21.9%) 0.78 0.61-1.00 0.04 0.80 0.59-1.07 0.14
G908R Polymorphism
Wild type 858 (90.8%) 626 (90.6%) 1.00 - - 1.00 - -
Hetero- or homozygote 87 (9.2%) 65 (9.4%) 0.98 0.70-1.37 0.89 1.00 0.67-1.53 0.96
1007fs Polymorphism
Wild type 735 (77.8%) 477 (69.0%) 1.00 - - 1.00 - -
Carrier of risk allele 210 (22.2%) 214 (31.0%) 0.64 0.51-0.80 7 × 10
-5 0.64 0.49-0.83 9 × 10
-4
* adjusted for sex, age at diagnosis, age at study inclusion, family history, and year of recruitment
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case-only design. Previous studies investigating gene-
environment interaction in CD [13,26] did not employ
the case-only design, which has been increasingly recog-
nised over the last two decades as an attractive method
for assessing the presence of statistical interaction
[29-32]. The case-only design offers substantial increases
in power as well as greater precision in estimating inter-
actions when compared to traditional case-control
designs [31].
Although our findings are promising, the current
study does have limitations. The main limitation is that
the case-only design only allows for the assessment of
statistical interactions under a multiplicative model,
which is considered by many epidemiologists to be less
meaningful than an additive scale [33]. Furthermore,
case-only designs are particularly sensitive to the
assumption of independence of the genetic and environ-
mental risk factors in the general population [34]. How-
ever, we observed no association between any of the
CD-associated risk alleles and history of ever having
smoked in a sample of 718 German population-based
controls, which supports the assumption that these risk
factors are independent. Additionally, a recent meta-
analysis suggests that bias in case-only studies is rare,
and no differences in OR estimates between traditional
case-control and case-only studies of gene-environment
interactions were observed [32]. Our study was further
limited by the definition of smoking status. In the ques-
tionnaire administered to participants, no definition of
active smoking was specified. Participants were asked
only if they had ever smoked, which may have led to
misclassification of the environmental variable among
some participants. However, if the rates of misclassifica-
tion of smoking status and genotypes are non-
differential, that is if the classification of smoking status
is independent of genotype classification, as one would
expect, misclassification would push the interaction OR
towards unity rather than generate an inflated estimate
of interaction [33].
Despite these limitations, statistical interaction repre-
sents a powerful tool to point to potentially meaningful
biological interaction. Evidence from functional studies
[35] and an animal model of the 1007fs polymorphism
[10] suggests that the protein product encoded by this
allele exhibits gain of function properties, resulting in an
impairment of innate immune tolerance towards com-
mensal bacteria. The three CD-associated NOD2 poly-
morphisms furthermore have been shown to cause a
failure to induce autophagy via ATG16L1, impairing
autophagic wrapping and removal of invading bacteria
[36]. It has also been observed that cigarette smoke
extract delays NOD2 mRNA expression and impairs
NOD2 functioning in intestinal epithelial cells [37]. It is
reasonable to then speculate that the detrimental gain of
function effects associated with the 1007fs associated
protein may be modulated by the biological effects of
cigarette smoking. The immunosuppressive properties of
nicotine, one of the best studied components of cigar-
ette smoke, are well-established [23] and have been
shown to persist several weeks after exposure [38].
Our study indicates that smoking may modify the
overall disease risk associated with established genetic
risk variants. Therefore, it is plausible to suggest that
similar gene-environment interactions may exist that
influence the clinical manifestations and severity of CD.
Indeed it has recently been demonstrated that cigarette
smoking interacts with CD risk alleles, including NOD2
variants, to influence disease location in patients with
CD [39]. Further research is necessary to elucidate the
Table 3 Departure from multiplicativity between CD-associated NOD2 alleles and smoking status at diagnosis among
patients with Crohn’s disease
Smoking status at diagnosis Unadjusted Adjusted*
Smoker at diagnosis Non-smoker at diagnosis OR 95% CI p-value OR 95% CI p-value
Combined Allele Analysis
Wild type at all 3 loci 311 (59.6%) 384 (50.5%) 1.00 - - 1.00 - -
Carrier of ≥ 1 risk allele 211 (40.4%) 377 (49.5%) 0.69 0.55-0.87 0.001 0.68 0.51-0.89 0.005
R702W Polymorphism
Wild type 429 (82.2%) 608 (79.9%) 1.00 - - 1.00 - -
Carrier of risk allele 93 (17.8%) 153 (20.1%) 0.86 0.65-1.14 0.30 0.82 0.57-1.16 0.27
G908R Polymorphism
Wild type 475 (91.0%) 689 (90.5%) 1.00 - - 1.00 - -
Carrier of risk allele 47 (9.0%) 72 (9.5%) 0.94 0.64-1.39 0.78 0.93 0.57-1.49 0.76
1007fs Polymorphism
Wild type 420 (80.5%) 524 (68.9%) 1.00 - - 1.00 - -
Carrier of risk allele 102 (19.5%) 237 (31.1%) 0.54 0.41-0.70 3 × 10
-6 0.53 0.39-0.73 7 × 10
-5
* adjusted for sex, age at diagnosis, age at study inclusion, family history, and year of recruitment
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onment interactions as well as to understand how beha-
viour modification could potentially benefit patients
carrying disease-associated NOD2 variants.
Conclusions
Our finding of a significant negative statistical interaction
between cigarette smoking and the 1007fs NOD2 poly-
morphism in patients with Crohn’sd i s e a s ei si n t r i g u i n g
and warrants further investigation in epidemiological and
functional studies. Confirmation of a mechanistic interac-
tion by which cigarette smoking modulates the risk asso-
ciated with disease-associated NOD2 alleles may be
important in not only better understanding the biological
mechanisms underlying CD pathogenesis, but also in
developing appropriate recommendations for individuals
at high risk of developing CD.
Methods
Study design
Individuals with Crohn’s disease (CD) were continuously
r e c r u i t e df r o m1 9 9 5t o2 0 1 0a sp a r to fo n g o i n gs t u d i e s
for identifying genetic factors in inflammatory bowel
diseases. Patients were ascertained from across Germany
through physician referrals based on a positive diagnosis
of CD. Established clinical, radiologic, and endoscopic
criteria were required to confirm the diagnosis of CD, as
previously described [40-42]. A peripheral venous blood
sample was obtained from each participant at time of
recruitment. Informed written consent was obtained
from all study participants. The study protocol was
approved by the ethics committee of the University
Medical Hospital Schleswig-Holstein at the Christian-
Albrechts-University of Kiel. All patients were recruited
through the popgen biobank [43].
Data collection
Study population
A total of 2430 German individuals with Crohn’s disease
were eligible for participation in the current study. Parti-
cipants were excluded from analyses if genotype data for
any of the three risk loci were unavailable or if they
were non-proband members of multiplex families and
thus related to other members of the study sample. Of
the multiplex families, only the index patients were
included in the final study sample. Participants were
included in the analysis only if genotype data were avail-
able for all three CD-associated NOD2 polymorphisms.
Genotype data were unavailable for 744 individuals,
excluding them from further analysis. We excluded a
further 50 participants, as they were non-proband mem-
bers of multiplex families. After exclusion of related
individuals and those with missing genotypes, a total of
1636 participants were available for analysis.
Smoking behaviour
Participants in the study were administered a written
questionnaire to obtain information on demographic
characteristics, disease specific information, general
medical history, family history, and history of active
cigarette smoking. Participants were asked to indicate if
they had ever been active smokers and were assigned
either a “never smoker” or “ever smoker” status accord-
ing to responses given in the questionnaire. Participants
were furthermore asked to indicate if they had been
smokers at the time of CD diagnosis. Participants desig-
nated as “ever smokers” were further subdivided into
either “smokers at time of diagnosis” or “non-smokers
at time of diagnosis”.
Genotyping
DNA was extracted from peripheral blood lymphocytes
from each participant using standard methods. The
R702W, G908R, and 1007fs polymorphisms were geno-
typed in all patients using TaqMan
® SNP genotyping
assays as previously described [14].
Statistical analysis
Demographic and risk factor variables for the included
and excluded participants were compared using a c
2 test
for categorical variables and the independent samples t-
test for continuous variables.
For the analysis of gene-environment interaction, we
examined the effect of three established NOD2 risk
polymorphisms (R702W, G908R, and 1007fs) and his-
tory of having ever smoked in patients with Crohn’s dis-
ease. We employed a case-only study design, which uses
data only from diseased individuals to estimate statistical
gene-environment interactions under a multiplicative
model, assuming that the genetic and environmental
exposures are independent within the general popula-
tion [29-31].
Genetic exposures were coded dichotomously (i.e. pre-
sent or absent) for all analyses. In an initial combined
allele analysis, participants who were carriers of at least
one of the three risk variants were combined into a sin-
gle group and compared to participants who were wild
type at all three loci. In order to determine which poly-
morphisms were contributing to the signal detected in
the combined variant analysis, we then performed sub-
sequent analyses of each polymorphism separately. To
investigate whether deviations from multiplicativity were
stronger amongst participants who were smokers at the
time of diagnosis, we performed a second set of analyses
examining smoking status at the time of CD diagnosis.
To assess departure from multiplicativity between the
presence of NOD2 polymorphisms and smoking status,
we performed logistic regression analyses in R version
2.10.1 [44]. Presence of the NOD2 risk allele(s) of the
polymorphism under consideration was designated as
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used as the predictor variable in the first set of analyses
and smoking status at the time of diagnosis was used as
the predictor variable in the second set of analyses. Pre-
sence of gene-environment interaction was tested using
a likelihood-ratio test in the regression model. Depar-
ture from multiplicativity between risk allele under con-
sideration and smoking status was described by
estimating odds ratios (ORs) for the interaction term in
the regression model and respective 95% confidence
intervals (CIs). Participants with wild type genotype and
who were classified as never having smoked or as non-
smokers at the time of CD diagnosis were used as the
reference group for all respective analyses. All analyses
were adjusted for the potential confounding effects of
sex, age at diagnosis, age at recruitment, family history
of IBD, and year of recruitment in a multiple logistic
regression model.
Power calculations were performed for the combined
allele analyses and for the analyses of each polymorph-
ism separately using Quanto version 1.2.4 [45,46]. A
case-only outcome design for gene-environment interac-
tions under a dominant genetic model was used. Estab-
lished estimates of disease prevalence [47], risk allele
frequencies in the German general population [16], and
smoking frequency in a German population-based con-
trol sample along with disease ORs associated with
cigarette smoking and CD-associated NOD2 variants
derived from meta-analyses [15,22] were used for power
calculations. Power curves for each of the eight analyses
performed are presented in Additional file 2: Figure S1
and Additional file 3: Figure S2. For the analyses of sta-
tistical interaction with history of ever having smoked,
the current study had 80% statistical power to detect an
interaction OR of 0.73 (combined allele analysis), 0.67
(R702W), 0.41 (G908R), and 0.70 (1007fs). Our study
had 80% statistical power to detect an interaction OR of
0.70 (combined allele analysis), 0.64 (R702W), 0.35
(G908R), and 0.67 (1007fs) for the analyses of interac-
tion with smoking status at the time of diagnosis.
Conservative Bonferroni correction for eight tests at
an overall alpha level of 0.05 was applied to all analyses
to correct for multiple comparisons.
Additional material
Additional file 1: Table S1. Sensitivity analysis comparing gene-
environment interaction between the entire analytic sample (n = 1636)
and a dataset excluding a subsample with incomplete smoking at
diagnosis data (n = 1186); all analyses adjusted for sex, age at diagnosis,
age at study inclusion, family history, and year of recruitment. Table S2.
Comparison of sex, age at disease diagnosis, age at study inclusion, and
family history of IBD for each of the CD-associated NOD2 risk variants
among all participants included in the final analytic sample (n = 1636).
Table S3. Comparison of demographic and risk variables between
participants included and excluded from the final analytic study sample.
Additional file 2: Figure S1. Estimates of statistical power to detect
various interaction ORs for each of the four analyses examining history of
ever having actively smoked. n = 1636.
Additional file 3: Figure S2. Estimates of statistical power to detect
various interaction ORs for each of the four analyses examining smoking
status at time of CD diagnosis. Combined allele analysis n = 1283.
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